The Asuragen Genetics portfolio employs our proprietary molecular chemistry and informatics capabilities to drive the evolution of precision medicine in inherited disorders.
The AmplideX® suite of products is designed to solve unmet testing needs in inherited genetic disorders. The technology overcame a 20-year challenge by reliably amplifying the FMR1 gene. This allowed researchers to gain a deeper understanding of fragile X syndrome, the most common known inherited cause of intellectual disability and autism.
Asuragen pioneered innovation in three major areas: Reduced complexity, optimised workflow and quality performance.